ContraFect (NASDAQ: CFRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.310 | -0.510 | -0.2000 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.
Other companies in ContraFect’s space includes: CytomX Therapeutics (NASDAQ:CTMX), Adverum Biotechnologies (NASDAQ:ADVM), OncoCyte (NASDAQ:OCX), Ambrx Biopharma (NYSE:AMAM) and TCR2 Therapeutics (NASDAQ:TCRR).
The latest price target for ContraFect (NASDAQ: CFRX) was reported by WBB Securities on Wednesday, June 8, 2022. The analyst firm set a price target for 7.00 expecting CFRX to rise to within 12 months (a possible 141.38% upside). 4 analyst firms have reported ratings in the last year.
The stock price for ContraFect (NASDAQ: CFRX) is $2.9 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for ContraFect.
ContraFect’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for ContraFect.
ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.